{"disease":{"id":"atypical-hemolytic-uremic","name":"atypical hemolytic uremic"},"drugs":{"marketed":[{"drug_id":"ravulizumab","indication_name":"Atypical hemolytic uremic syndrome (aHUS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ultomiris","generic_name":"RAVULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitor [EPC]","quality_score":75,"revenue":"5100","mechanism":"Ultomiris blocks the action of Complement C5 to prevent inflammation and damage to red blood cells."},{"drug_id":"eculizumab-aeeb","indication_name":"Atypical Hemolytic Uremic Syndrome (aHUS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"BKEMV","generic_name":"ECULIZUMAB-AEEB","company_name":"AMGEN INC","drug_phase":"marketed","molecular_target":"","drug_class":"Complement Inhibitor [EPC]","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"eculizumab","indication_name":"Atypical hemolytic uremic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"H5G1.1","generic_name":"ECULIZUMAB","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"C5","drug_class":"Complement Inhibitor [EPC]","quality_score":56,"revenue":null,"mechanism":"Eculizumab-aeeb binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation."},{"drug_id":"ravulizumab-cwvz","indication_name":"Atypical hemolytic uremic syndrome (aHUS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"ULTOMIRIS","generic_name":"RAVULIZUMAB-CWVZ","company_name":"ALEXION PHARM","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ultomiris","indication_name":"Atypical hemolytic uremic syndrome (aHUS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ultomiris","company_name":"Alexion Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"soliris","indication_name":"Atypical hemolytic uremic syndrome","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Soliris","company_name":"Apellis Pharmaceuticals, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06065852","title":"National Registry of Rare Kidney Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"UK Kidney Association","has_results":false},{"nct_id":"NCT01522183","title":"Atypical Hemolytic-Uremic Syndrome (aHUS) Registry","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06099236","title":"A Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns and Outcomes in Atypical Hemolytic Uremic Syndrome Patients","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":367,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT07218536","title":"The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT03605511","title":"TTP and aHUS in Complicated Pregnancies","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"University College, London","has_results":false},{"nct_id":"NCT05795140","title":"Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT05805202","title":"Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy","phase":"NA","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT04861259","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":83,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT07399730","title":"Ravulizumab Outcomes in Polish Patients With aHUS","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT06312644","title":"Study of Ultomiris® (Ravulizumab) Safety in Pregnancy","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02614898","title":"Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment","phase":"","overall_status":"TERMINATED","enrollment_count":67,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02949128","title":"Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":58,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03574506","title":"Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia","has_results":false},{"nct_id":"NCT05935215","title":"Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04749810","title":"Observational Study of Elizaria® in aHUS Patients","phase":"","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"AO GENERIUM","has_results":false},{"nct_id":"NCT04745195","title":"Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium","phase":"","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04958265","title":"A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":41,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT04889430","title":"Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":34,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03131219","title":"Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01770951","title":"A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05876351","title":"Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03518203","title":"Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Children's Hospital Medical Center, Cincinnati","has_results":true},{"nct_id":"NCT07308574","title":"Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02464891","title":"Complement Inhibition in aHUS Dialysis Patients","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Mario Negri Institute for Pharmacological Research","has_results":false},{"nct_id":"NCT03205995","title":"Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":6,"lead_sponsor_name":"Omeros Corporation","has_results":true},{"nct_id":"NCT01757431","title":"The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT03303313","title":"A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Alnylam Pharmaceuticals","has_results":false}],"total":27},"guidelines":[],"source":"Drug Landscape verified database"}